Cheng-Chia Lee1,2,3, Michael A Reardon4, Benjamin Z Ball1, Ching-Jen Chen1, Chun-Po Yen1, Zhiyuan Xu1, Max Wintermark5, Jason Sheehan1,6. 1. Departments of 1 Neurological Surgery. 2. Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital; 3. School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China; and. 4. Radiology & Medical Imaging, Neuroradiology Division, University of Virginia Health System, Charlottesville, Virginia; 5. Department of Radiology, Stanford University, Palo Alto, California. 6. Radiation Oncology, and.
Abstract
OBJECT: The current gold standard for diagnosing arteriovenous malformation (AVM) and assessing its obliteration after stereotactic radiosurgery (SRS) is digital subtraction angiography (DSA). Recently, MRI and MR angiography (MRA) have become increasingly popular imaging modalities for the follow-up of patients with an AVM because of their convenient setup and noninvasiveness. In this study, the authors assessed the sensitivity and specificity of MRI/MRA in evaluating AVM nidus obliteration as assessed by DSA. METHODS: The authors study a consecutive series of 136 patients who underwent SRS between January 2000 and December 2012 and who underwent regular clinical examinations, several MRI studies, and at least 1 post-SRS DSA follow- up evaluation at the University of Virginia. The average follow-up time was 47.3 months (range 10.1-165.2 months). Two blinded observers were enrolled to interpret the results of MRI/MRA compared with those of DSA. The sensitivity, specificity, positive predictive value, and negative predictive value for the obliteration of AVM were reported. RESULTS: On the basis of DSA, 73 patients (53.7%) achieved final angiographic obliteration in a median of 28.8 months. The sensitivity (the probability of finding obliteration on MRI/MRA among those for whom complete obliteration was shown on DSA) was 84.9% for one observer (Observer 1) and 76.7% for the other (Observer 2). The specificity was 88.9% and 95.2%, respectively. The false-negative interpretations were significantly related to the presence of draining veins, perinidal edema on T2-weighted images, and the interval between the MRI/MRA and DSA studies. CONCLUSIONS: MRI/MRA predicted AVM obliteration after SRS in most patients and can be used in their follow-up. However, because the specificity of MRI/MRA is not perfect, DSA should still be performed to confirm AVM nidus obliteration after SRS.
OBJECT: The current gold standard for diagnosing arteriovenous malformation (AVM) and assessing its obliteration after stereotactic radiosurgery (SRS) is digital subtraction angiography (DSA). Recently, MRI and MR angiography (MRA) have become increasingly popular imaging modalities for the follow-up of patients with an AVM because of their convenient setup and noninvasiveness. In this study, the authors assessed the sensitivity and specificity of MRI/MRA in evaluating AVM nidus obliteration as assessed by DSA. METHODS: The authors study a consecutive series of 136 patients who underwent SRS between January 2000 and December 2012 and who underwent regular clinical examinations, several MRI studies, and at least 1 post-SRS DSA follow- up evaluation at the University of Virginia. The average follow-up time was 47.3 months (range 10.1-165.2 months). Two blinded observers were enrolled to interpret the results of MRI/MRA compared with those of DSA. The sensitivity, specificity, positive predictive value, and negative predictive value for the obliteration of AVM were reported. RESULTS: On the basis of DSA, 73 patients (53.7%) achieved final angiographic obliteration in a median of 28.8 months. The sensitivity (the probability of finding obliteration on MRI/MRA among those for whom complete obliteration was shown on DSA) was 84.9% for one observer (Observer 1) and 76.7% for the other (Observer 2). The specificity was 88.9% and 95.2%, respectively. The false-negative interpretations were significantly related to the presence of draining veins, perinidal edema on T2-weighted images, and the interval between the MRI/MRA and DSA studies. CONCLUSIONS: MRI/MRA predicted AVM obliteration after SRS in most patients and can be used in their follow-up. However, because the specificity of MRI/MRA is not perfect, DSA should still be performed to confirm AVM nidus obliteration after SRS.
Authors: Daniel Umansky; Benjamin W Corn; Ido Strauss; Natan Shtraus; Shlomi Constantini; Vladimir Frolov; Shimon Maimon; Andrew A Kanner Journal: Childs Nerv Syst Date: 2018-06-07 Impact factor: 1.475
Authors: A Jhaveri; A Amirabadi; P Dirks; A V Kulkarni; M M Shroff; N Shkumat; T Krings; V M Pereira; V Rea; P Muthusami Journal: AJNR Am J Neuroradiol Date: 2019-06-27 Impact factor: 3.825
Authors: Grant S Roberts; Michael W Loecher; Alma Spahic; Kevin M Johnson; Patrick A Turski; Laura B Eisenmenger; Oliver Wieben Journal: Magn Reson Med Date: 2021-12-31 Impact factor: 4.668
Authors: Yi-Chieh Hung; Nasser Mohammed; Kathryn N Kearns; Ching-Jen Chen; Robert M Starke; Hideyuki Kano; John Lee; David Mathieu; Anthony M Kaufmann; Wei Gang Wang; Inga S Grills; Christopher P Cifarelli; John Vargo; Tomas Chytka; Ladislava Janouskova; Caleb E Feliciano; Rafael Rodriguez-Mercado; L Dade Lunsford; Jason P Sheehan Journal: Neurosurgery Date: 2020-05-01 Impact factor: 4.654
Authors: Ching-Jen Chen; Dale Ding; Cheng-Chia Lee; Kathryn N Kearns; I Jonathan Pomeraniec; Christopher P Cifarelli; David E Arsanious; Roman Liscak; Jaromir Hanuska; Brian J Williams; Mehran B Yusuf; Shiao Y Woo; Natasha Ironside; Rebecca M Burke; Ronald E Warnick; Daniel M Trifiletti; David Mathieu; Monica Mureb; Carolina Benjamin; Douglas Kondziolka; Caleb E Feliciano; Rafael Rodriguez-Mercado; Kevin M Cockroft; Scott Simon; Heath B Mackley; Samer G Zammar; Neel T Patel; Varun Padmanaban; Nathan Beatson; Anissa Saylany; John Y K Lee; Jason P Sheehan Journal: J Neurosurg Date: 2020-12-11 Impact factor: 5.408
Authors: Tobias Greve; Felix Ehret; Theresa Hofmann; Jun Thorsteinsdottir; Franziska Dorn; Viktor Švigelj; Anita Resman-Gašperšič; Joerg-Christian Tonn; Christian Schichor; Alexander Muacevic Journal: Front Oncol Date: 2021-03-09 Impact factor: 6.244